Skip to content
2000
Volume 7, Issue 1
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background

The use of antiviral therapies in addressing COVID-19 infection has been subject to varying approaches across different jurisdictions during the initial two years of the pandemic, with ivermectin being permitted in some regions, while banned in others.

Objective

This study aimed to comprehensively review the evidence surrounding the efficacy of ivermectin, specifically in combating COVID-19 infection.

Methods

The efficacy of ivermectin has been assessed through an extensive review of scientific literature. Additionally, a comparative analysis has been conducted, evaluating cases and fatalities in states and countries that either have embraced or rejected ivermectin and other antiviral treatments.

Results

A thorough examination of the scientific literature has revealed a predominantly positive trend supporting the utilization of ivermectin, evident in works published up to October 2021 and continuing in subsequent publications. Insights drawn from 217 studies have indicated improvements of 85%, 62%, and 41% for prophylaxis, early treatment, and late treatment, respectively. This positive effect, particularly in prophylaxis, has been further substantiated by analyzing cases and fatalities during the mid-2021 Indian outbreak. The success of the ivermectin-based Uttar Pradesh kit has been highlighted by the notably expedited reduction in cases and fatalities compared to other Indian states employing alternative approaches. Moreover, when contrasting countries that have prohibited ivermectin and other antivirals (., the United States and the United Kingdom) with nations endorsing various antiviral strategies, including ivermectin, or with historical use of ivermectin (., Africa, India, Saudi Arabia, or the United Arab Emirates), the advantages of endorsing rather than discouraging antiviral therapies have become evident.

Conclusion

The majority of scientific literature has been found to support the use of ivermectin against COVID-19 infection, consistent with the lesser impact of COVID-19 infections observed in Indian states that have either utilized or abstained from ivermectin, as well as in countries that have either adopted or rejected antiviral treatments.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975311764240819092551
2024-08-26
2026-01-03

  • From This Site

    /content/journals/covid/10.2174/0126667975311764240819092551
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Possible coronavirus drug identified by Melbourne scientists.2020Available from: www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists(accessed on 25-7-2024)
  2. CalyL. DruceJ.D. CattonM.G. JansD.A. WagstaffK.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res.202017810478710.1016/j.antiviral.2020.10478732251768
     [Google Scholar]
  3. UTTAR PRADESH Going the last mile to stop COVID-19.2021Available from: https://www.who.int/india/news/feature-stories/detail/uttar-pradesh-going-the-last-mile-to-stop-covid-19(accessed on 25-7-2024)
  4. HoftJ. Watch: Dr. Campbell Reveals the Reason Behind India’s Ivermectin Blackout2021 https://www.thegatewaypundit.com/2021/10/dr-campbell-reveals-reason-behind-indias-ivermectin-blackout/[accessed June 26, 2025].
  5. KoryP. McCarthyJ. War on ivermectin: The medicine that saved millions and could have ended the pandemic.Simon and Schuster2023
     [Google Scholar]
  6. VineS. 2024. Saying Farewell to the Famous Horse Tweet: Why the FDA must delete its statement that people are not horses (or cows), referring to ivermectin use. https://themedicinemaker.com/business-regulation/saying-farewell-to-the-famous-horse-tweet-concerning-ivermectin[accessed June 26, 2025].
  7. ZaidiA.K. Dehgani-MobarakiP. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review.J. Antibiot. (Tokyo)2022752607110.1038/s41429‑021‑00491‑634931048
     [Google Scholar]
  8. LehrerS RheinsteinPH Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2 in vivo.202034530233026
     [Google Scholar]
  9. EweasA.F. AlhossaryA.A. Abdel-MoneimA.S. Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2.Front. Microbiol.20211159290810.3389/fmicb.2020.59290833746908
     [Google Scholar]
  10. ChoudhuryA. DasN.C. PatraR. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach.Future Virol.202116427729110.2217/fvl‑2020‑0342
     [Google Scholar]
  11. YangS.N.Y. AtkinsonS.C. WangC. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.Antiviral Res.202017710476010.1016/j.antiviral.2020.10476032135219
     [Google Scholar]
  12. RizzoE. Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action.Naunyn Schmiedebergs Arch. Pharmacol.202039371153115610.1007/s00210‑020‑01902‑532462282
     [Google Scholar]
  13. Dueñas-GonzálezA. Juárez-RodríguezM. Ivermectin: Potential repurposing of a versatile antiparasitic as a novel anticancer.In Drug Repurposing-Molecular Aspects and Therapeutic Applications.2021IntechOpen
     [Google Scholar]
  14. Dominguez-GomezG. Chavez-BlancoA. Medina-FrancoJ.L. Ivermectin as an inhibitor of cancer stem like cells.Mol. Med. Rep.201817233973403[PMID: 29257278
     [Google Scholar]
  15. HeidaryF. GharebaghiR. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen.J. Antibiot. (Tokyo)202073959360210.1038/s41429‑020‑0336‑z32533071
     [Google Scholar]
  16. WagstaffK.M. RawlinsonS.M. HearpsA.C. JansD.A. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import.SLAS Discov.201116219220010.1177/108705711039036021297106
     [Google Scholar]
  17. BennettS.M. ZhaoL. BosardC. ImperialeM.J. Role of a nuclear localization signal on the minor capsid Proteins VP2 and VP3 in BKPyV nuclear entry.Virology201547411011610.1016/j.virol.2014.10.01325463609
     [Google Scholar]
  18. RazaS. ShahinF. ZhaiW. Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication.Microorganisms20208340910.3390/microorganisms803040932183205
     [Google Scholar]
  19. ArshadU. PertinezH. BoxH. Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics.Clin. Pharmacol. Ther.2020108477579010.1002/cpt.190932438446
     [Google Scholar]
  20. SwargiaryA. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: evidence from in silico studies.Research Square202010.21203/rs.3.rs‑73308/v1
     [Google Scholar]
  21. MaY. WuL. ShawN. Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex.Proc. Natl. Acad. Sci. USA2015112309436944110.1073/pnas.150868611226159422
     [Google Scholar]
  22. ModyV. HoJ. WillsS. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.Commun. Biol.2021419310.1038/s42003‑020‑01577‑x33473151
     [Google Scholar]
  23. SethC. MasC. ConodA. Long-lasting WNT-TCF response blocking and epigenetic modifying activities of Withanolide F in human cancer cells.PLoS One20161112e016817010.1371/journal.pone.016817027973612
     [Google Scholar]
  24. ZhangX. SongY. CiX. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.Inflamm. Res.2008571152452910.1007/s00011‑008‑8007‑819109745
     [Google Scholar]
  25. JiangL. WangP. SunY.J. WuY.J. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.J. Exp. Clin. Cancer Res.201938126510.1186/s13046‑019‑1251‑730606223
     [Google Scholar]
  26. MatsuyamaT. KubliS.P. YoshinagaS.K. PfefferK. MakT.W. An aberrant STAT pathway is central to COVID-19.Cell Death Differ.202027123209322510.1038/s41418‑020‑00633‑733037393
     [Google Scholar]
  27. DouQ. ChenH.N. WangK. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer.Cancer Res.201676154457446910.1158/0008‑5472.CAN‑15‑288727302166
     [Google Scholar]
  28. de MeloG.D. LazariniF. LarrousF. Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin.EMBO Mol. Med.2021138e1412210.15252/emmm.20211412234170074
     [Google Scholar]
  29. LayhadiJ.A. TurnerJ. CrossmanD. FountainS.J. ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages.J. Immunol.201820031159116810.4049/jimmunol.170096529255078
     [Google Scholar]
  30. JuarezM. Schcolnik-CabreraA. Dueñas-GonzalezA. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.Am. J. Cancer Res.201882317331[PMID: 29511601
     [Google Scholar]
  31. CiX. LiH. YuQ. Avermectin exerts anti‐inflammatory effect by downregulating the nuclear transcription factor kappa‐B and mitogen‐activated protein kinase activation pathway.Fundam. Clin. Pharmacol.200923444945510.1111/j.1472‑8206.2009.00684.x19453757
     [Google Scholar]
  32. YanS. CiX. ChenN. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma.Inflamm. Res.201160658959610.1007/s00011‑011‑0307‑821279416
     [Google Scholar]
  33. ZaidiA.K. DawoodiS. PirroM. MontiM. MobarakiP.D. Key role of annexin A2 and plasmin in COVID-19 pathophysiology, clinical presentation and outcomes—a review. Ital J Prev.Diagn Ther Med2020320202024
     [Google Scholar]
  34. ScheimD. Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion.SSRN2020Available from: papers.ssrn.com/sol3/papers.cfm?abstract_id=3636557(accessed on 15-7-2024)
     [Google Scholar]
  35. NagaiH. SatomiT. AbiruA. Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia.EBioMedicine20172414715810.1016/j.ebiom.2017.09.02228942281
     [Google Scholar]
  36. BorettiA. BanikB.K. More widespread use of Ivermectin for the treatment of COVID-19 Infection could have saved many.Curr. Organocatal.2024112899410.2174/2213337210666230809141610
     [Google Scholar]
  37. Estimated cumulative excess deaths per 100,000 people during COVID-19, Jun 17,2024.2023Available from: ourworldindata.org/explorers/coronavirus-data-explorer(accessed on 25-7-2024)
    [Google Scholar]
  38. BryantA. LawrieT.A. DowswellT. Ivermectin for prevention and treatment of COVID-19 infection: A systematic review, meta-analysis and trial sequential analysis to inform clinical guidelines.Am. J. Ther.2021284e434e46010.1097/MJT.000000000000140234145166
     [Google Scholar]
  39. KoryP. MeduriG.U. VaronJ. IglesiasJ. MarikP.E. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19.Am. J. Ther.2021283e299e31810.1097/MJT.000000000000137734375047
     [Google Scholar]
  40. c19ivm.org, 2025. Ivermectin for COVID-19. https://c19ivm.org/[accessed July 1, 2025]
  41. c19studies, 2023.2023Available from: c19ivm.org/(accessed on 25-7-2024)
  42. ChowdhuryA.T.M.M. ShahbazM. KarimM.R. IslamJ. GuoD. HeS. A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.Eurasian J. Med. Oncol.2021516370
     [Google Scholar]
  43. Espitia-HernandezG. MunguiaL. Diaz-ChiguerD. Lopez-ElizaldeR. Jimenez-PonceF. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study.Biomed. Res.2020315129133
     [Google Scholar]
  44. HectorC. RobertoH. Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirina against COVID-19 the IDEA protocol.J. Clin. Trials202111459
     [Google Scholar]
  45. MahmudR. RahmanM.M. AlamI. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: A randomized trial.J. Int. Med. Res.202149510.1177/0300060521101355033983065
     [Google Scholar]
  46. CadegianiF.A. GorenA. WambierC.G. McCoyJ. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.New Microbes New Infect.20214310091510.1016/j.nmni.2021.10091534249367
     [Google Scholar]
  47. AhmedS. KarimM.M. RossA.G. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.Int. J. Infect. Dis.202110321421610.1016/j.ijid.2020.11.19133278625
     [Google Scholar]
  48. ChaccourC. CasellasA. Blanco-Di MatteoA. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.EClinicalMedicine20213210072010.1016/j.eclinm.2020.10072033495752
     [Google Scholar]
  49. GhauriMI AfsarNA AbbasM MukarramMS PerachaMY IshaqK Ivermectin use associated with reduced duration of COVID-19 febrile illness in a community setting.The Lancet10.2139/ssrn.3734478
     [Google Scholar]
  50. BabalolaO.E. BodeC.O. AjayiA.A. Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos.QJM20221141178078810.1093/qjmed/hcab03533599247
     [Google Scholar]
  51. RavikirtiR. RoyR. PattadarC. Ivermectin as a potential treatment for mild to moderate COVID-19–a double blind randomized placebo-controlled trial.J. Pharm. Pharm. Sci.20212434335010.18433/jpps3210534265236
     [Google Scholar]
  52. Shah BukhariK.H. AsgharA. PerveenN. 2021Efficacy of ivermectin in COVID-19 patients with mild to moderate disease.MedRxiv202102022125084010.1101/2021.02.02.21250840
     [Google Scholar]
  53. MohanA. TiwariP. SuriT.M. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.J. Infect. Chemother.202127121743174910.1016/j.jiac.2021.08.02134483029
     [Google Scholar]
  54. BiberA. HarmelinG. LevD. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial.Int. J. Infect. Dis.202212273374010.1016/j.ijid.2022.07.00335811080
     [Google Scholar]
  55. ElalfyH. BesheerT. El-MeseryA. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19.J. Med. Virol.20219353176318310.1002/jmv.2688033590901
     [Google Scholar]
  56. ChahlaR.E. RuizL.M. MenaT. Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers.Res Soc Develop2022118e3551183084410.33448/rsd‑v11i8.30844
     [Google Scholar]
  57. MouryaS. ThakurA.S. HadaD.S. KulshreshthaV.S. SharmaY. Comparative analytical study of two different drug regimens in treatment of COVID-19 positive patients in Index Medical College Hospital and Research Center, Indore, India.Int J Heal Clin Res202146265267
     [Google Scholar]
  58. LouéP. FardeauC. Ivermectin and COVID-19 in care home: Case report.J. Infect. Dis. Epidemiol.202174
     [Google Scholar]
  59. FaisalR. ShahS.F.A. HussainM. Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19.Prof. Med. J.202128573774110.29309/TPMJ/2021.28.05.5867
     [Google Scholar]
  60. ArefZ.F. BazeedS.E.E.S. HassanM.H. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19.Int. J. Nanomed2021164063407210.2147/IJN.S31309334163159
     [Google Scholar]
  61. MayerM.A. KrolewieckiA. FerreroA. Safety and efficacy of a MEURI program for the use of high dose ivermectin in COVID-19 patients.Front. Public Heal20221081337810.3389/fpubh.2022.81337835273939
     [Google Scholar]
  62. Ascencio-MontielI.J. Tomás-LópezJ.C. Álvarez-MedinaV. A multimodal strategy to reduce the risk of hospitalization/death in ambulatory patients with COVID-19.Arch. Med. Res.202253332332810.1016/j.arcmed.2022.01.00235123809
     [Google Scholar]
  63. ManomaipiboonA. PholtawornkulchaiK. PoopipatpabS. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: A randomized, double-blind, placebo-controlled trial.Trials202223171410.1186/s13063‑022‑06649‑336028897
     [Google Scholar]
  64. MirahmadizadehA. SematiA. HeiranA. Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID ‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial.Respirology202227975876610.1111/resp.1431835738778
     [Google Scholar]
  65. SchillingW.H.K. JittamalaP. WatsonJ.A. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).eLife202312e8320110.7554/eLife.8320136803992
     [Google Scholar]
  66. ShoumannW.M. HegazyA.A. NafaeR.M. Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: A randomized clinical trial.J. Clin. Diagn. Res.202115210786010.7860/JCDR/2021/46795.14529
     [Google Scholar]
  67. CarvalloH.E. Usefulness of topic ivermectin and carrageenan to prevent contagion of COVID-19.Patent NCT044258502020
     [Google Scholar]
  68. HéctorC RobertoH PsaltisA VeronicaC Study of the efficacy and safety of topical ivermectin+ iota-carrageenan in the prophylaxis against COVID-19 in health personnel.J biomed res clin investig2020211007
     [Google Scholar]
  69. BernigaudC. GuillemotD. Ahmed-BelkacemA. Grimaldi-BensoudaL. LespineA. BerryF. Ivermectin benefit: From scabies to COVID-19, an example of serendipity.Ann. Dermatol. Venereol.202014712
     [Google Scholar]
  70. AlamM.T. MurshedR. GomesP.F. Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka–an observational study.Euro J Med Heal Sci20202659910.24018/ejmed.2020.2.6.599
     [Google Scholar]
  71. ChahlaR.E. Medina RuizL. OrtegaE.S. Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina.Am. J. Ther.2021285e601e60410.1097/MJT.000000000000143334491960
     [Google Scholar]
  72. Desort-HeninV. KostovaA. BabikerE.A. CaramelA. MalamutR. The SAIVE Trial, Post-exposure use of ivermectin in COVID-19 prevention: Efficacy and safety results.Patent NCT053055602021
     [Google Scholar]
  73. MondalS. SinghaA. DasD. Prevalence of covid-19 infection and identification of risk factors among asymptomatic healthcare workers: A serosurvey involving multiple hospitals in west bengal.J. Indian Med. Assoc.202111952128
     [Google Scholar]
  74. López-MedinaE. LópezP. HurtadoI.C. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial.JAMA2021325141426143510.1001/jama.2021.307133662102
     [Google Scholar]
  75. ChahlaR.E. Medina RuizL. MenaT. 2021Ivermectin reproposing for COVID-19 treatment outpatients in mild stage in primary health care centers.MedRxiv20210310.1101/2021.03.29.21254554
     [Google Scholar]
  76. MerinoJ. BorjaV.H. LopezO. Ivermectin and the odds of hospitalization due to COVID-19: Evidence from a quasi-experimental analysis based on a public intervention in Mexico City (No. r93g4). Center for Open Science.2021Available from: https://osf.io/preprints/socarxiv/r93g4_v1 (accessed on 25-7-2024)
  77. BramanteC.T. HulingJ.D. TignanelliC.J. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19.N. Engl. J. Med.2022387759961010.1056/NEJMoa220166236070710
     [Google Scholar]
  78. SamajdarS.S. MukherjeeS. MondalT. PaulJ. TripathiS.K. ChakrbartyA. SahaB. BhattacharryaD. TripathiR. Ivermectin and hydroxychloroquine for chemo-prophylaxis of COVID-19: a questionnaire survey of perception and prescribing practice of physicians vis-à-vis outcomes.J. Assoc. Physicians India202169111416
     [Google Scholar]
  79. The epoch times,2023 https://www.theepochtimes.com/article/doctors-can-prescribe-ivermectin-for-covid-19-fda-5456584 [accessed August 14, 2023].
  80. Reuters, 2021. 2015 Nobel Prize for ivermectin intended for treatment of parasitic infections doesn’t prove its efficacy on COVID-19. https://www.reuters.com/article/factcheck-nobel-ivermectin-idUSL1N2QB2XA/[accessed August 14, 2023].
  81. SantinA.D. ScheimD.E. McCulloughP.A. YagisawaM. BorodyT.J. Ivermectin: A multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19.New Microbes New Infect.20214310092410.1016/j.nmni.2021.10092434466270
     [Google Scholar]
  82. Press release.2015Available from: www.nobelprize.org/prizes/medicine/2015/press-release/(accessed on 25-7-2024)
  83. c19early, 2025. COVID-19 early treatment: real-time analysis of 5,917 studies. https://c19early.org/ [accessed July 1, 2025]
  84. LedfordH. MaxmenA. African clinical trial denied access to key COVID drug Paxlovid.Nature20226047906412413
     [Google Scholar]
  85. LiuJ. PanX. ZhangS. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: A multicenter randomized controlled study.Lancet Reg. Heal West. Pacific.20233310069410.1016/j.lanwpc.2023.10069436777445
     [Google Scholar]
  86. YuZ. ZhengY. ChenB. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.Phytomedicine202312015502510.1016/j.phymed.2023.15502537639813
     [Google Scholar]
  87. HoertelN. BoulwareD.R. Sánchez-RicoM. BurgunA. LimosinF. Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease.JAMA Netw. Open2022511e224214010.1001/jamanetworkopen.2022.4214036378313
     [Google Scholar]
  88. KerrL. CadegianiF.A. BaldisF. LoboR.B. AssagraW.L.O. ProençaF.C. KoryP. HibberdJ.A. Chamie-QuinteroJ.J. LoboR. Assagra SrW.L. PIvermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching.Cureus2022141
     [Google Scholar]
/content/journals/covid/10.2174/0126667975311764240819092551
Loading
Reviewing Ivermectin’s Efficacy in Treating COVID-19 Infection
Coronaviruses 7, E26667975311764 (2026); https://doi.org/10.2174/0126667975311764240819092551
/content/journals/covid/10.2174/0126667975311764240819092551
/content/journals/covid/10.2174/0126667975311764240819092551
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antivirals; COVID-19; in vitro; ivermectin; parasitic organisms; viral RNA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test